Staar Surgical Valuation Multiples

Staar Surgical Overview

About Staar Surgical

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Founded

1982

HQ

Employees

1.2K

Website

staar.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $260M

EBITDA: $6M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Staar Surgical Financials

Staar Surgical reported last 12-month revenue of $260M and EBITDA of $6M.

In the same LTM period, Staar Surgical generated $197M in gross profit, $6M in EBITDA, and had net loss of ($56M).

Staar Surgical P&L

In the most recent fiscal year, Staar Surgical reported revenue of $310M and EBITDA of $36M.

Staar Surgical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Staar Surgical Stock Performance

Staar Surgical has current market cap of $1B, and enterprise value of $1B.

Staar Surgical's stock price is $25.08.

Staar Surgical Valuation Multiples

Staar Surgical trades at 4.2x EV/Revenue multiple, and 174.3x EV/EBITDA.

Staar Surgical Financial Valuation Multiples

As of April 20, 2026, Staar Surgical has market cap of $1B and EV of $1B.

Equity research analysts estimate Staar Surgical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Staar Surgical has a P/E ratio of (22.1x).

Staar Surgical Margins & Growth Rates

Staar Surgical's revenue in the last 12 month grew by 22%.

Staar Surgical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Staar Surgical's rule of 40 is (16%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Staar Surgical's rule of X is (16%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Staar Surgical Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Staar Surgical M&A Activity

Staar Surgical acquired XXX companies to date.

Last acquisition by Staar Surgical was on XXXXXXXX, XXXXX. Staar Surgical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Staar Surgical Investment Activity

Staar Surgical invested in XXX companies to date.

Staar Surgical made its latest investment on XXXXXXXX, XXXXX. Staar Surgical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).